Who is sponsoring NCT04401878?

NCT04401878 is sponsored by Zagazig University.

What drugs are being tested in NCT04401878?

Interventions in NCT04401878: Sphenopalatine Ganglion Block using 2% lidocaine.

What condition does NCT04401878 study?

NCT04401878 studies Post-Dural Puncture Headache.

Is NCT04401878 still recruiting?

NCT04401878 is currently completed. Last updated 22 July 2021.

Last reviewed 2021-07-22 · How we verify

NCT04401878

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SGB in Management of Patients With PDPH Using TCD

Completed NA Last updated 22 July 2021

What this trial tests

NA trial testing Sphenopalatine Ganglion Block using 2% lidocaine in Post-Dural Puncture Headache in 120 participants. Completed in 20 September 2020.

Timeline

24 May 2020

Primary endpoint
20 September 2020

20 September 2020

Quick facts

Lead sponsor	Zagazig University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	24 May 2020
Primary completion	20 September 2020
Estimated completion	20 September 2020
Sites	1 location across Egypt

Drugs / interventions tested

Sphenopalatine Ganglion Block using 2% lidocaine — full drug profile →

Conditions studied

Post-Dural Puncture Headache — all drugs for Post-Dural Puncture Headache →

Sponsor

Zagazig University

Who can join

Adults 18 to 60, any sex, with Post-Dural Puncture Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the ability of SPGB in the management of PDPH. Transcranial Doppler is also used as an measure to assess the block success by detecting the variability in the cerebral hemodynamics before and after the block.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sphenopalatine Ganglion Block using 2% lidocaine

Trials testing the same drug.

NCT06735261 — Sphenopalatine Block in Headache in Patients With Non-traumatic Subarachnoid Hemorrhage · NA · not yet recruiting

Other Zagazig University trials

Trials by the same sponsor.

NCT07423676 — Comparison Between Two Drugs in Sedation of Upper GI Endoscopy · not yet recruiting
NCT07418307 — Comparison Between Combined Biceps Femoris Short Head Block and Adductor Canal Block Versus Genicular Nerve Block · NA · not yet recruiting
NCT07435025 — Surgery for Obstructed Gastric Carcinoma · NA · active not recruiting
NCT07330375 — Effect of Intravenous Dexmedetomidine and Ketamine on Post-Operative Analgesia · Phase 3 · not yet recruiting
NCT07309731 — Impact OF Cooled Versus Thermal Radiofrequency Denervation In Management Of Chronic Lumber Facet Joint Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04401878 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zagazig University
Last refreshed: 22 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04401878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing